Sugi Predict

Sugi Predict / Compounds / SCHEMBL2394449

SCHEMBL2394449

SCHEMBL2394449

CN(CC1CCC(NC(=O)OC(C)(C)C)CC1)c1ccc(I)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 8/20 0.46
▸ KDM1A O60341 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ DRD3 P35462 2/20 0.42
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KCNA3 P22001 1/20 0.39
▸ EPHX2 P34913 1/20 0.38
▸ JAK1 P23458 2/20 0.38
▸ BTK Q06187 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ CKS1B P61024 1/20 0.36
▸ SKP1 P63208 1/20 0.36
▸ SKP2 Q13309 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394446 1.00 DRD2 (0.46) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2391001 0.87 DRD2 (0.45) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2390996 0.87 DRD2 (0.45) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2392750 0.86 EPHX1 (0.40) DRD2DRD3CKS1BSKP1SKP2
SCHEMBL2392752 0.86 EPHX1 (0.40) DRD2DRD3CKS1BSKP1SKP2
SCHEMBL2390499 0.86 DRD2 (0.42) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2390497 0.86 DRD2 (0.42) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2393433 0.84 DRD2 (0.42) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL2393427 0.84 DRD2 (0.42) DRD2KDM1AMAOBDRD3KMT2A
SCHEMBL15342780 0.83 DRD2 (0.42) DRD2KDM1AMAOBDRD3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 — — US disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
EP-4121043-A1 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
US-9073898-B2 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2015-07-07 — — US disclosed
US-9051279-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2015-06-09 — — US disclosed
US-8969351-B2 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2015-03-03 — — US disclosed
EP-2640467-B1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2014-12-17 — — EP disclosed
EP-2516009-B1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2014-09-24 — — EP disclosed
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES NOVARTIS AG (CH) 2013-10-24 — — US disclosed
EP-2640467-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION Novartis AG (CH) 2013-09-25 — — EP disclosed
US-20130245036-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2013-09-19 — — US disclosed
US-8440693-B2 Substituted isoquinolinones and quinazolinones NOVARTIS AG (CH) 2013-05-14 — — US disclosed
EP-2516009-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES Novartis AG (CH) 2012-10-31 — — EP disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
WO-2012066095-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 DRD2 4088/4885KDM1A 822/4885MAOB 2461/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 DRD2 3978/4885KDM1A 304/4885MAOB 3459/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 DRD2 3318/4885KDM1A 397/4885MAOB 2510/4885
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 DRD2 1974/4885KDM1A 1216/4885MAOB 1800/4885
US-20130245036-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION MDM4, TP53, TP53BP1 DRD2 4207/4885KDM1A 2248/4885MAOB 4071/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 DRD2 4088/4885KDM1A 822/4885MAOB 2461/4885
US-20130281473-A1 SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES MDM4, MDM2, TP53 DRD2 1974/4885KDM1A 1216/4885MAOB 1800/4885
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction MDM4, TP53, TP53BP1 DRD2 4240/4885KDM1A 2349/4885MAOB 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.